Actinium Pharmaceuticals Inc

Research Actinium Pharmaceuticals Inc (ATNM) on Bullrun: market cap USD 31.06M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerATNM
• ExchangeNYSE MKT
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 31.06M
• Financial periodFY2025
• RevenueUSD 90.00K
• Net income-USD 33.89M
• Free cash flow-USD 24.68M

Valuation Snapshot

latest market cap is USD 31.06M.

About Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. The company offers Actimab-A, a CD33 targeting radiotherapeutic for patients with Relapsed/Refractory AML which is in to a Phase 2/3 Trial; and Iomab-ACT, to improve patient access to and outcomes with cellular therapies, such as CAR-T and gene therapies for non-malignant hematologic disorders such as sickle cell disease.

Frequently asked questions

What is Actinium Pharmaceuticals Inc's market cap?

Actinium Pharmaceuticals Inc's market capitalization is USD 31.06M.

What does Actinium Pharmaceuticals Inc do?

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies.